558 related articles for article (PubMed ID: 18836691)
1. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
3. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Deramo VA; Lai JC; Fastenberg DM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
[TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
5. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
6. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
7. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
[TBL] [Abstract][Full Text] [Related]
9. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Mather R; Karenchak LM; Romanowski EG; Kowalski RP
Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
[TBL] [Abstract][Full Text] [Related]
10. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Park SH; Lim JA; Choi JS; Kim KA; Joo CK
Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
[TBL] [Abstract][Full Text] [Related]
11. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
13. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
14. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
15. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
McCulley JP; Caudle D; Aronowicz JD; Shine WE
Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Hwang DG
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
[TBL] [Abstract][Full Text] [Related]
18. [Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia].
Galvis V; Tello A; Guerra A; Acuña MF; Villarreal D
Biomedica; 2014 Apr; 34 Suppl 1():23-33. PubMed ID: 24968033
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin prophylaxis in neutropenic patients.
von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
